Investigational Drug Details
| Drug ID: | D012 |
| Drug Name: | Apararenone |
| Synonyms: | MT-3995 |
| Type: | Chemical drug |
| DrugBank ID: | DB15024 |
| DrugBank Description: | Apararenone is under investigation in clinical trial NCT02531568 (Drug Interaction Study of Warfarin and MT-3995). |
| PubChem ID: | 24744336 |
| CasNo: | 945966-46-1 |
| Repositioning for NAFLD: | No |
| SMILES: | O=C1N(c2c(OC1(C)C)cc(cc2)NS(=O)(=O)C)c1ccc(cc1)F |
| Structure: |
|
| InChiKey: | AZNHWXAFPBYFGH-UHFFFAOYSA-N |
| Molecular Weight: | 364.398 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | Aldosterone receptor |
| Therapeutic Category: | Improve insulin resistance |
| Clinical Trial Progress: | Phase 2 completed (NCT02923154) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |